A French study published Online First in The Lancet has revealed that fractionizing the dosage of the targeted anticancer drug gemtuzumab ozogamicin allows for safer delivery of the drug into patients between the ages of 50 to 70 years with acute myeloid leukemia (AML) and significantly improves their outcomes. Earlier research has demonstrated that although gemtuzumab ozogamicin can cause AML to go into remission, the dosing regimen meant frequent reports of complications, such as liver toxicity and veno-occlusive disease...
More...
More...